Tech, health stocks rise, cyclicals fall on prospects of divided U.S. Congress

Benchmark Reiterates Buy Rating on Alibaba (BABA)

November 6, 2020 7:20 AM EST

Benchmark analyst Fawne Jiang reiterated a Buy rating and $355.00 price target on Alibaba (NYSE: BABA) following the company's 2Q earnings report. BABA reported F2Q21 results with largely in-line revenue and better-than-expected Adj. EBITDA and EPADS.

The Company continued to acquire... More

Vulcan Materials (VMC) Misses Q3 EPS by 6c, Revenues Miss

November 5, 2020 7:33 AM EST

Vulcan Materials (NYSE: VMC) reported Q3 EPS of $1.56, $0.06 worse than the analyst estimate of $1.62. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.37 billion.

Tom Hill, Chairman and Chief Executive Officer, said, "Building on strong performance from the first half of the year, our operational execution produced another quarter of unit margin expansion in the third quarter. Unit profitability gains were widespread across our footprint, and our team remained focused on driving those improvements. The continued impact of the COVID-19 pandemic on construction activity, along with severe... More

Regeneron (REGN) Tops Q3 EPS by $1.23, Revenues Beat

November 5, 2020 6:50 AM EST

Regeneron (NASDAQ: REGN) reported Q3 EPS of $8.36, $1.23 better than the analyst estimate of $7.13. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.09 billion.

Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4)Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019Third quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 69% to $1.07 billion versus third quarter 2019Third quarter 2020 GAAP diluted EPS was $7.39... More

Cigna Corp. (CI) Tops Q3 EPS by 17c, Revenues Beat; Raises FY20 Revenue Guidance, Provides FY20 EPS Outlook

November 5, 2020 6:05 AM EST

Cigna Corp. (NYSE: CI) reported Q3 EPS of $4.41, $0.17 better than the analyst estimate of $4.24. Revenue for the quarter came in at $41 billion versus the consensus estimate of $39.18 billion.

Total revenues in the third quarter were $41.0 billion. Adjusted revenues1 were $40.8 billion.Shareholders' net income for the third quarter was $1.4 billion, or $3.78 per shareAdjusted income from operations2 for the third quarter was $1.6 billion, or... More

FDA Giving Biogen (BIIB) Option for Aducanumab Approval on Efficacy from ENGAGE Trial, Shares Worth $443 on Approval - Truist

November 4, 2020 10:54 AM EST

Truist Securities analyst Robyn Karnauskas weighed in on the FDA briefing documents for Biogen's (NASDAQ: BIIB) aducanumab, saying the FDA is giving BIIB the option for approval based on efficacy data from one trial (ENGAGE).

The analyst commented, "While we continue to review the FDA... More

CoreCivic (CXW), GEO Group (GEO) Plunge 15% and 11% Respectively

November 4, 2020 9:39 AM EST

CoreCivic (NYSE: CXW), GEO Group (NYSE: GEO) Plunge 15% and 11% Respectively

Weakness in Prison Stocks Appears Tied to Election Outcome
... More